Psychedelic Therapy for Eating Disorders

Actions Panel

Psychedelic Therapy for Eating Disorders

The PAC" Industry Presents Series" Sponsored by Numinus

By Psychedelic Association of Canada

When and where

Date and time

Thu, Jun 15, 2023 4:00 PM - 5:30 PM PDT



Refund Policy

Contact the organizer to request a refund.
Eventbrite's fee is nonrefundable.

About this event

  • 1 hour 30 minutes
  • Mobile eTicket

The use of psychedelics, combined with psychotherapy, may be very effective in addressing hard to treat eating disorders. We will review relevant research, along with medical, legal and safety frameworks for psychedelic assisted therapy for treat eating disorders. We will also explore the therapeutic potential of altered states of consciousness and how psychedelic therapy could be integrated into conventional eating disorder therapy models.

Dr. Pamela Kryskow - Host & PAC Board Member

Dr. Pamela Kryskow is a medical doctor in Vancouver, British Columbia. Her training includes Family Medicine, Rural Emergency Medicine, Chronic pain, Functional Medicine and Psychedelic Assisted Psychotherapy. She is currently working with colleagues on research related to Psychedelic Assisted Psychotherapy, Microdosing, MDMA, Psilocybin, Chronic Pain and Psychedelic therapy. She is the medical lead in Roots To Thrive Non Profit and the Medical Chair of the Vancouver Island University Psychedelic Assisted Therapy Post Graduate Certificate Program and a Clinical Instructor at UBC.

Reid Robison- MD, MBA, Chief Clinical Officer - Numinus

Dr. Reid Robison is a board-certified psychiatrist who was named Best Psychiatrist in Utah by Salt Lake City Weekly’s Best of Utah Body & Mind 2020. Dr. Robison is the co-founder of Cedar Psychiatry and serves as the Medical Director for the Center for Change, a leading Eating Disorder center.

He was previously a coordinating investigator for the MAPS-sponsored MDMA-assisted psychotherapy study of eating disorders. As an early adopter and researcher of ketamine in psychiatry, Dr. Robison led a pivotal IV ketamine study for treatment-resistant depression by Janssen, leading up to the company’s recent FDA-approval of Spravato™. To date, Dr. Robison has guided thousands of ketamine therapy journeys and hundreds of Spravato™ dosing sessions.

As a social entrepreneur, Dr. Robison has built a number of purpose-driven companies including Tute Genomics which was acquired by PierianDx in 2016. Dr. Robison is also an adjunct professor at both the University of Utah and Brigham Young University and is the founder of the Polizzi Free Clinic, a free mental health clinic for marginalized people based in Salt Lake City, Uta

About the organizer

Uniting Canada's Psychedelic Community. We stand for the responsible and empowered use of psychedelics.